Quick Answer
Denali Therapeutics Inc. reported Operating Income Loss of -$555.34 million for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -14.0% in Operating Income Loss from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$21.74 million | Q2 2017: -$22.57 million | Q3 2017: -$22.29 million | Q4 2017: -$23.54 million | Q1 2018: -$25.75 million | Q2 2018: -$57.38 million | Q3 2018: -$37.96 million | Q4 2018: $74.72 million | Q1 2019: -$42.51 million | Q2 2019: -$62.76 million | Q3 2019: -$50.16 million | Q4 2019: -$57.76 million | Q1 2020: -$59.97 million | Q2 2020: -$61.28 million | Q3 2020: -$60.12 million | Q1 2021: -$71.22 million | Q2 2021: -$61.82 million | Q3 2021: -$85.59 million | Q1 2022: -$66.50 million | Q2 2022: -$61.42 million | Q3 2022: -$107.49 million | Q1 2023: -$120.82 million | Q2 2023: $170.48 million | Q3 2023: -$113.80 million | Q1 2024: -$117.72 million | Q2 2024: -$116.59 million | Q3 2024: -$123.19 million | Q1 2025: -$145.58 million | Q2 2025: -$134.96 million | Q3 2025: -$137.43 million.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Operating Income Loss has declined by 535.2%.
- Historical annual values: Fiscal year 2025: -$555.34 million | Fiscal year 2024: -$487.34 million | Fiscal year 2023: -$196.70 million | Fiscal year 2022: -$340.74 million | Fiscal year 2021: -$295.75 million | Fiscal year 2020: $62.72 million | Fiscal year 2019: -$213.18 million | Fiscal year 2018: -$46.37 million | Fiscal year 2017: -$90.14 million | Fiscal year 2016: -$87.43 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: